An Open-Label, Sequential, Ascending Single-Dose Safety, Tolerability, Pharmacokinetic and Pharmacodynamics Study of an Intravenous Infusion of SEL-037 in Subjects With Elevated Blood Uric Acid Levels
Phase of Trial: Phase I
Latest Information Update: 24 Oct 2016
At a glance
- Drugs Pegadricase (Primary)
- Indications Gout; Tumour lysis syndrome
- Focus Adverse reactions; Proof of concept
- Sponsors 3SBio
- 19 Oct 2016 Status changed from active, no longer recruiting to completed.
- 15 Apr 2016 Planned End Date changed from 1 Jan 2016 to 1 Jul 2016.
- 01 Dec 2015 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.